This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners Losers

K-Swiss (KSWS) slouched on disappointing financials. The Westlake Village, Calif., maker of apparel and footwear said it earned $10.7 million in the fourth quarter, or 30 cents a share, down from $11.6 million, or 33 cents a share, a year ago. Sales inched up 1.7% to $93.8 million year over year, just past the $92.3 million consensus. Income, however, missed targets by a penny.

Looking ahead, the company is pegging full-year 2007 earnings between $1.20 and $1.50 a share, a far cry from the $2.17 per-share income sought by analysts. Full-year revenue will probably range between $420 million and $460 million, nearly $40 million below the Street projection. Shares were declining $4.05, or 12.1%, to $29.44.

Emergent BioSolutions' (EBS) stock got a black eye on word the biotech company had lost a funding opportunity when the National Institute of Allergy and Infectious Diseases canceled its solicitation for bids to develop a "third-generation anthrax vaccine," to which Emergent had responded after the NIAID issued it last June. Shares were off $1.33, or 8.9%, to $13.70.

G-III Apparel (GIII) cut its revenue forecast to a range of $425 million to $428 million for the year ended Jan. 31, from the prior $430 million, just missing the only analyst's estimate of $429.8 million. The New York-based outerwear maker also reaffirmed its full-year earnings outlook of between 90 cents and 95 cents a share, which resides largely below two analysts' expectations, each of whom is looking for 94 cents a share. These numbers all represent substantial growth from 2005, but shares were losing $3.43, or 13%, to $22.94.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EMAG $20.48 -0.17%
ICTG $26.00 7.22%
BRKR $22.65 0.00%
HDNG $9.61 -0.57%
AAPL $117.82 -0.18%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs